Table 2.
Approved LNP Drugsa
| Name | Encapsulated Drug | Indication | Year Approved | Company |
|---|---|---|---|---|
| AmBisome | amphotericin B | Fungal infections Leishmanaisis | 1990 (Europe), 1997 (USA) | Gilead |
| Doxil/Caelyx | doxorubicin | Kaposi’s sarcoma | 1995 (USA) | Johnson & Johnson |
| ovarian cancer | 1999 (USA) | |||
| breast cancer | 2003 (Europe, Canada) | |||
| DaunoXome | daunorubicin | Kaposi’s sarcoma | 1996 (Europe), 1996 (USA) | Galen |
| Myocet | doxorubicin | breast cancer | 2000 (Europe) | Cephalon |
| Abelcet | amphotericin B | Aspergillosis | 1995 (USA) | Enzon |
| Amphotec | amphotericin B | Aspergillosis | 1996 (USA) | Intermune |
| Visudyne | verteporphin | macular degeneration | 2000 (USA), 2003 (Japan) | QLT |
| Lipo-Dox | doxorubicin | Kaposi’s sarcoma, breast, and ovarian cancer | 2001 (Taiwan) | Taiwan Liposome |
| Marqibo | vincristine | acute lymphoblastic leukemia | 2012 (USA) | Spectrum Pharma |
LNP, lipid nanoparticle.
a
Administered by intravenous injection.